Actively Recruiting
Pilot Study to Evaluate Immune Response After Histotripsy Treatment for Liver Metastases in Colorectal Cancer Patients
Led by Northwell Health · Updated on 2026-01-22
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the immune response in patients with colorectal cancer that has spread to the liver. This pilot study focuses on how a non-invasive treatment called histotripsy affects the immune system, especially the T-cells in the blood. Histotripsy is approved by the FDA to treat liver tumors, and this study aims to understand how disrupting tumors with this method might change immune activity. The investigators hope the findings will guide future combined treatments with immunotherapy for colorectal cancer that is resistant to certain immune drugs. Participants will receive histotripsy treatment targeting their liver metastases as part of the study. This is a single-center, non-randomized, open-label study without comparison groups, focusing only on the effects of histotripsy. The study involves monitoring changes in immune system markers by collecting blood samples before and after the histotripsy procedure. The goal is to observe how T-cell populations expand or show signs of exhaustion following treatment. During the study, participants will have multiple blood draws to track immune responses over time. Researchers will measure changes in immune cells, particularly T-cells, to understand systemic effects of the local tumor treatment. The main outcome is the measurement of immune modulation via T-cells over a two-year period. Safety and participant health will be monitored, with the study lasting up to two years to capture detailed immune changes after histotripsy.
CONDITIONS
Brief Title
Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here